Business Context and Reporting Period
Milestone Pharmaceuticals Inc. (MIST), an emerging growth company incorporated in Québec, filed this Form 8-K on May 15, 2021. The report details a strategic partnership and a concurrent private placement of equity securities.
Key Financial Metrics and Transaction Terms
- Upfront Cash Payment: $15 million from Ji Xing Pharmaceuticals, Limited.
- Milestone Payments: Up to $107.5 million in potential development and sales milestones.
- Royalties: Tiered payments ranging from low double digits to high double digits of Net Sales in the Territory.
- Private Placement Proceeds: Approximately $5.0 million gross proceeds from the sale of pre-funded warrants.
- Equity Issuance: 910,746 pre-funded warrants at $5.48 per warrant.
Material Changes and Agreements
License and Collaboration Agreement
The Company entered into an agreement with Ji Xing Pharmaceuticals, Limited (affiliated with RTW Investments, LP, a ~14% shareholder) to grant exclusive development and commercialization rights for etripamil nasal spray in the People's Republic of China, Hong Kong, Macau, and Taiwan. Ji Xing will handle development and regulatory activities, while Milestone retains certain manufacturing responsibilities pending a supply agreement.
Unregistered Sales of Equity Securities
The Company agreed to sell pre-funded warrants to affiliates of RTW in a private placement expected to close around May 21, 2021. The warrants have an initial exercise price of $0.01 per share, no expiration date, and are immediately exercisable, subject to a 9.99% beneficial ownership limitation.
Outlook, Risks, and Contingencies
- Termination Rights: Ji Xing may terminate for convenience with 180 days' notice. Either party may terminate for material breach or bankruptcy. Milestone may terminate if Ji Xing challenges the Company's patent rights.
- Joint Governance: A Joint Steering Committee will be established to oversee strategy and operations.
- Regulatory Status: The filing notes that the full text of the License Agreement and securities purchase agreement will be filed with the SEC, with confidential terms redacted.
Investor Verification Checklist
- Verify the closing date and final proceeds of the $5.0 million private placement.
- Confirm the specific percentage tiers for royalty payments once the full agreement is filed.
- Monitor the establishment of the Joint Steering Committee and the execution of the contemplated supply agreement.
- Review the impact of the 9.99% beneficial ownership cap on the exercise of pre-funded warrants by RTW affiliates.